What is Dianthus Therapeutics Inc. (DNTH) stock price today?

Dianthus Therapeutics Inc. (DNTH) currently trades at $87.12 per share. The stock has a market capitalization of $4.67B and a P/E ratio of —x.

Is DNTH stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Dianthus Therapeutics Inc. has a Smart Value Score of 22/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Dianthus Therapeutics Inc.'s revenue and earnings?

Dianthus Therapeutics Inc. has trailing twelve-month (TTM) revenue of $1.34M with profit margins of 0.00%. Earnings per share (EPS) is $-4.23.

DNTH

Dianthus Therapeutics Inc.

NASDAQ: DNTH · HEALTHCARE · BIOTECHNOLOGY

$87.12

+0.47% today

Updated 2026-05-11

Market cap

$4.67B

P/E ratio

—

P/S ratio

3,497.25x

EPS (TTM)

$-4.23

Dividend yield

—

52W range

$17 – $97

Volume

1.0M

Market cap

$4.67B

P/E ratio

—

P/S ratio

3,497.25x

EPS (TTM)

$-4.23

Dividend yield

—

52W range

$17 – $97

Volume

1.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →198 stocks currently score above 75

Price targets

Analyst target

$126.38

+45.06%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy16 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-28.87M

- Revenue declining -60.20% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$6.42M	$2.83M	$6.24M	$2.04M	$1.34M
Net income	$-28.48M	$-43.55M	$-84.97M	$-162.34M	$-40.83M
EPS	—	—	—	—	$-4.23
Free cash flow	$-29.21M	$-36.97M	$-78.28M	$-129.27M	$-28.87M
Profit margin	-443.76%	-1,541.22%	-1,362.77%	-7,973.33%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DNTH	$4.67B	22	2.7	2.5	5.0	5.0	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-37.47%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-19.74%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+40.60%	Buy
AZN	$283.47B	62	6.0	8.5	5.3	5.0	+6.51%	Buy

Smart narrative

Dianthus Therapeutics Inc. trades at $87.12. Our Smart Value Score of 22/100 indicates the stock is weak. TTM revenue stands at $1.34M.

Frequently asked questions

What is Dianthus Therapeutics Inc.'s stock price?

Dianthus Therapeutics Inc. (DNTH) trades at $87.12.

Is Dianthus Therapeutics Inc. overvalued?

Smart Value Score 22/100 (Grade F, Strong Sell).

What is the price target of Dianthus Therapeutics Inc. (DNTH)?

The analyst target price is $126.38, representing +45.1% upside from the current price of $87.12.

What is Dianthus Therapeutics Inc.'s revenue?

TTM revenue is $1.34M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio3,497.25x

ROE-22.70%

Beta0.09

50D MA$81.79

200D MA$48.34

Shares out0.05B

Float0.05B

Short ratio—

Avg volume1.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

DNTH vs LLY →DNTH vs JNJ →DNTH vs ABBV →Stock screener →